Reviewers: GAO Hui, WANG Xi-cheng, LAI Xiao-rong. A Phase Ⅰb Clinical Study of Regorafenib Plus Nivolumab in Patients With Advanced Gastric Cancer or Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(4): 217-221. DOI: 10.12019/j.issn.1671-5144.2020.04.005
|
Citation:
|
Reviewers: GAO Hui, WANG Xi-cheng, LAI Xiao-rong. A Phase Ⅰb Clinical Study of Regorafenib Plus Nivolumab in Patients With Advanced Gastric Cancer or Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(4): 217-221. DOI: 10.12019/j.issn.1671-5144.2020.04.005
|
Reviewers: GAO Hui, WANG Xi-cheng, LAI Xiao-rong. A Phase Ⅰb Clinical Study of Regorafenib Plus Nivolumab in Patients With Advanced Gastric Cancer or Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(4): 217-221. DOI: 10.12019/j.issn.1671-5144.2020.04.005
|
Citation:
|
Reviewers: GAO Hui, WANG Xi-cheng, LAI Xiao-rong. A Phase Ⅰb Clinical Study of Regorafenib Plus Nivolumab in Patients With Advanced Gastric Cancer or Colorectal Cancer[J]. Journal of Evidence-Based Medicine, 2020, 20(4): 217-221. DOI: 10.12019/j.issn.1671-5144.2020.04.005
|
DownLoad: